Tumor Whole-Genome Sequencing Influences Care in 40%+ Patients
Why should tumor whole genome sequencing (WGS) be done for cancer? In real practice of medicine study of 888 patients with solid cancers, WGS directly led to clinical consequences in over 40% @NatureMedicine https://t.co/kFho0yuLS7
Biotech Giant Earendil Labs Secures $787M Funding
Giant biotech round that hit right after I sent Pro Rata: Earendil Labs raises $787M https://t.co/NWt2bBA9Lr
AI Deciphers Life’s Language in New Nature Biotech Review
AI to understand the language of life. Our review @NatureBiotech just published https://t.co/i0WMaXBCHl Free access https://t.co/3LPulNxlD0 @VishRao5 @serena2z @BrianPlosky @pdhsu @BoWang87 @james_y_zou @marinkazitnik @pranavrajpurkar
Promising Therapeutics' Future at Risk Under Trump FDA
The future of promising therapeutics is on the line in the Trump administration's FDA, says the agency's former commissioner https://t.co/vyt49FkDsb
Rebuilding Vaccine Trust After Ideologically Flawed ACIP Recommendations
Good news for America’s children. ACIP was devoid of vaccine expertise and made harmful and ideologically driven recommendations that went against pediatric medical science. Hopefully we can rebuild pubic confidence in vaccines despite their efforts to undermine it, but it...
Epigenetic Age Acceleration Links to MRI Aging Markers
Association of epigenetic age acceleration with MRI biomarkers of aging and Alzheimer's disease neurodegeneration https://t.co/VSJVp4MYij
NVS
$NVS paying $2bn for Synnovation's SNV4818, after $LLY paid $1.5bn for Scorpion's STX-478. Mechanistically, seems like good news for $RLAY, bad for $OKUR & $COGT
ML and Quantum Computing Unite for Next‑Gen Drug Discovery
#compchem #machinelearning #quantumcomputing New preprint: "The Convergence Frontier: Integrating Machine Learning and High Performance Quantum Computing for Next-Generation Drug Discovery". @qubit_pharma https://t.co/4D23DV0uAk
New Terminal Plasmid Editor Simplifies Golden Braid Domestication
Making good progress on my vibecoded mutagenesis tool. Now it makes golden braid part domestication easy too. I may disappoint Patrick and just make a plasmid editor that works inside your terminal with external GUI libraries necessary aside from Textual...
Single-Cell Clocks Offer Precise Insight Into Aging
Single-cell aging clocks: A precision tool for dissecting and targeting the aging process https://t.co/5e47qWtZwH https://t.co/ImfBb45luO
Continuous-Flow VAD Keeps Patients Alive Pre‑Transplant
Life Without a Pulse: Continuous-Flow VAD That Sustains Patients Awaiting Transplants by @Doctors__squad #HealthTech #Innovation #EmergingTech #Tech #Technology #TechForGood https://t.co/KoRFzmH3lQ
Mid‑session Unblinding Doesn’t Equal Procedural Equivalence
But one set of trials (TAD) were open label and other set of trials (psychedelic) included impt elements of experimental control, procedures like randomization and blinding. Does functional unblinding mid-session justify treating these trials as procedurally equivalent? No.
FDA’s Post‑Prasad Path: Six Drugmakers, Six Months
This week's Biotech Scorecard newsletter: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era $REPL Pierre Fabre $ATRA $QURE $CAPR $RGNX https://t.co/sGa7G6YTDn
Stress Triggers Skin Inflammation via Newly Identified Neural Circuit
New @ScienceMagazine Discovery of a circuit that connects stress and skin inflammation https://t.co/Dkmmcs96JT https://t.co/chrXyKrG2N https://t.co/7nOPn9fCoU
Genentech Exits SMA Program, Boosting SRRK’s Lead
Very positive development for $SRRK - Genentech ceases drug development to spinal muscular atrophy - puts SRRK clearly in the lead Cantor on it now https://t.co/IjCyBm2Kcv
Gene Therapy Delivers Real Results Amid Hype
Katrine Bosley: There's no question “hopes and aspirations” got ahead of the pace of any new science on gene editing #STATBreakthrough Seng Cheng: “The promise of gene therapy is correct. I think it has made that promise. and that's demonstrated by...
Early Experiments May Mislead; Models Need Validation
Jane Grogan from $BIIB again, on the fundamental challenge of drug discovery: do you believe what early experiments tell you? "We need to understand when [models] can be predictive and when they help at answering our hypothesis... “If you...
China Produces Triple U.S. PhDs, Boosting Biotech Innovation
$BIIB’s Jane Grogan on the impact of China on biotech innovation. “There's three times more PhDs that have been given last year in China than in the US. ... That's a lot of bright young things out there who are going...
Higher GLP‑1 Doses Show Cardiac Safety Signal
This definitely looks like a cardiac safety signal at the higher doses. The GLP-1's all slightly increase pulse rate as a starting point.
Breakthroughs Take Years, Then Appear Overnight
$BMY chief scientist Robert Plenge: says there is “a joke” drug developers often repeat. “It's an overnight sensation a decade in the making. These things can actually be going on for a very long time, and then suddenly the field catches...
FT Highlights CRUK's Aleta CAR‑T Trial in Lymphoma
The Financial Times covered recent initiatives at Cancer Research UK (CRUK) including a nice piece on the ongoing Aleta Biotherapeutics clinical trial in CD19-CAR-T treated B cell lymphoma patients. https://t.co/9sDZEItapu
Analysts Underestimate ATAI's Expanding Psychedelic Market Potential
$ATAI is currently covered by 13 analysts, with price targets spanning $7 to $25. I believe though that the view of most investors and analysts on @ataibeckley appears largely anchored only to the initial lead indication and drug we are pursuing:...
Oral Ozempic Trials Fail to Show Alzheimer's Benefit
The negative oral Ozempic randomized trials (EVOKE, EVOKE+) for Alzheimer's disease have now been published @TheLancet https://t.co/Xx0YknTSC2
GLP‑1 Drugs May Protect Heart, Vessels, Kidneys in Type 1 Diabetes
GLP-1 drugs have established benefit for Type 2 diabetes. New data suggests that extends to Type 1 diabetes, with heart, vascular, and kidney protection https://t.co/nZDKHoFIRm https://t.co/lTHIgoj4ir
Prioritize Affinity, Specificity, Then Stability in Nanobody Design
Okay here's a game - you're making nanobody therapeutics. AI can help you optimise them, but you need to prioritise order of feature importance. What is your order? Affinity Specificity Expressibility Clinical toxicity In vivo stability Purified stability Patentability Other?
Claude Code Workflow Unlocks Extended Thinking in Genomics
1/ My last thread on Claude use cases got a lot of attention. The number one question: "how do you actually use extended thinking for biology?" Here's my exact Claude Code workflow for genomics questions where regular prompting falls short.
Vaccines Shield Vulnerable Populations; Declining Rates Endanger Protection
Multiple vaccines offer benefits beyond protecting the vaccinated individual from the disease the vaccine targets. Some protect fetuses in the womb, some protect people who are immunocompromised, some protect seniors. As vax rates fall, these benefits are threatened. https://t.co/zmiws8gAnw
FDA Lets Sarepta Push Failed Drugs, Blocks UniQure
Let's look at how the FDA is treating $SRPT and $QURE differently. The FDA grants accelerated approval to Amondys and Vyondys to treat Duchenne muscular dystrophy. Sarepta conducts a post-marketing confirmatory study that fails to show a benefit for either...
Congruence Launches First Drug, Secures $40M Funding
Exclusive: Clarissa Desjardins' newest biotech has put its first drug in the clinic + raised $40M more. Congruence also expects to put 2 more molecules into clinic in early 2027, seeing its platform driving its R&D efficiency: https://t.co/pzxcnmKFBj
New DNA Base Editor Cuts Off‑target Edits, Keeps Efficiency
A newly engineered DNA base editor significantly reduces bystander edits while maintaining high on-target efficiency, offering a more precise tool for gene therapy and genetic research. geneediting
Implant vs Meds: Randomized Trial Questions LAA Closure Benefit
Questioning the benefit of an implant to close the left atrial appendage vs medical therapy in a randomized trial @NEJM https://t.co/N0hpdIfmLe https://t.co/8bkk8FzLuY
Biotech Whisperer Adam May Joins Podcast Tomorrow
Excited to have fintwit's biotech whisperer, @A_May_MD , on the podcast tmr. We'll be talking all things biotech and maybe some $NKTR and $ABVX. Any questions for Adam?
Stopping GLP‑1 Therapy Quickly Erodes Cardiovascular Protection
A new finding after stopping GLP-1 drugs in a large cohort with Type 2 diabetes: rapid erosion of CV benefit/protection New @bmj_latest by @zalaly @Biostayan https://t.co/JG6yB8wTJJ See thread: https://t.co/6JvfIIjVBw https://t.co/wUgWhvs9Yy
In‑body Genome Editing Promises Cheaper, Practical CAR‑T Therapies
What if we could engineer T cells in the body, making CAR T vs cancer, autoimmune diseases, and other applications far more practical, much less expensive? A step forward today via genome editing T cells https://t.co/FjgQA8NUlu https://t.co/XXk43WL1ac https://t.co/rpC7eCAlJH
Brain Organoids Play Video Game, Demonstrating Cellular Computing
It's the future it's possible that we'll use cells plus silicon for compute. In this experiment, scientists used a mouse brain organoid (brain-in-a-dish) to play a video game, showing living cells can solve digital tasks. Reaching 46% proficiency in a...
Repeated Psilocybin Doses Yield 73% OCD Response
A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder 73.3% were responders (⩾35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6 months. https://t.co/tp2SPIKDrB
MRK Unveils PD-1/VEGF Bispecific at AACR26
$MRK's PD-1 x VEGF bispecific reveal, & other key #AACR26 presentations, via @APEXONCO -> https://t.co/ob1eswxCWF $RVMD $AMGN $GILD $BCYC $SDGR
RBC Flags Revolution, Xenon, Arrowhead as Top Biotech Takeover Targets
RBC: Revolution, Xenon, Arrowhead among top #biotech takeover targets https://t.co/h1toH9szrU by @realJacobBell $ARWR $XENE $RVMD $DYNE
5‑MeO‑DMT Shows Promise for Treatment‑Resistant Depression
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger randomized controlled trials. https://t.co/6CcEOSat1F
Mitochondrial Transfer Shows Promise Against Parkinson’s in Animals
Potential of mitochondrial transfer to prevent or treat Parkinson' s disease, in mouse and monkey models @CellCellPress https://t.co/c0oqfagddX https://t.co/KyBc1zQttc
Trillion Gene Atlas: Cool Concept, No Data Yet
Well, I love PacBio generally and the Trillion Gene Atlas sounds kind of cool. But as far as I can tell, none of this has been released publically and I cannot find a paper or preprint on the Trillion...
Comparing Psychedelic Trials to Antidepressants Skews Results
Does it stack the deck in favor of the standard antidepressants to pull data from placebo-controlled trials for one condition (the psychedelic) and compare it with single condition data for the standard antidepressants? Also...
Statistical Significance ≠ Biological Meaning in Bioinformatics
1/ Bioinformatics is NOT just statistics. The p-value is small, but is it biologically meaningful? Let’s talk. 🧵 https://t.co/gJ4s3Sjtr4
Key Strategies for Building Biotech: Science, Tech, Finance
It was a fun privilege to share a few thoughts on building biotechs with Nature Biotechnology for their 30th Anniversary issue - covering a broad range of topics including translating science into medicines, technology cycles, and financing biotech companies... https://t.co/LbnWMSJI9f
FT‑Targeted Biotech Stocks Deliver Short‑Term Alpha
Good read on Biopharma M&A by RBC , little mention to Betaville, Bloomberg, FT , oand ofc the standout $RVMD Our biopharma team is out with an M&A discussion piece - given the importance of M&A to the sector, it is...
CTMX Shows Higher ORR Than Temab‑A, Needs Validation
Late line CRC therapies in development following $CTMX's data this week (from Guggenheim). A lot is riding on $CTMX's 10 mg/kg cohort which had just 19 evaluable patients (3 patients were excluded so ITT response rate is lower) so this needs...
Hookworm Vaccine Achieves Near‑100% Protection in Phase 2
Some exciting news tonight just published @TheLancetInfDis our @TexasChildrens @BCM_TropMed @GWSMHS hookworm anemia vaccine is showing high levels of protective immunity in human phase 2 clinical trials, nearly 100% reduction in hookworm, a project of decades https://t.co/C23cNdsa0p
AlphaFold Adds Millions of Complexes, Illuminating Protein Interactions
Millions of protein complexes added to AlphaFold Database shed light on how proteins interact https://t.co/Kt9oFFkAf2 https://t.co/tEnlYOTCPl
AI's Real Bottleneck: Accelerating Human Processes, Not Tech
Our bottleneck for some of the biggest change ahead may be humans. I shared the story of Paul Conyngham and his dog Rosie on my Instagram when it broke. When I read the coverage, my shock was less that ChatGPT...
GIP Drives Subcutaneous Fat Storage; Tirzepatide Leverages This
GIP preferentially enhances glucose storage and triglyceride deposition in healthier subcutaneous fat, particularly under conditions of hyperinsulinemia and hyperglycemia. Tirzepatide contains a GIP agonist. https://doi.org/10.2337/db10-0098 https://www.gatlan.com/ @GatlanHealth
